Answers are grounded in this paper and cite their sources.
Lung cancer remains a leading cause of cancer mortality, with chemotherapy resistance limiting treatment efficacy. Citri Exocarpium Rubrum (CER), a flavonoid-rich traditional Chinese medicine, exhibits anticancer potential. This study investigated its antioxidant and antiproliferative effects against A549 lung cancer cells and the underlying mechanisms. Flavonoids were extracted from CER and partitioned into ethyl acetate and n-butanol fractions. Antioxidant capacity and antiproliferative effects were assessed by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively. Mitochondrial membrane potential (MMP) and apoptosis were measured. Network pharmacology was conducted using TCMSP, SwissTargetPrediction and GeneCards, followed by GO and KEGG enrichment analyses. Both fractions showed concentration-dependent DPPH radical scavenging (73.66% and 84.36% at 32 μg/mL) and inhibited A549 proliferation. The n-butanol fraction induced dose-dependent apoptosis with reduced MMP. Network pharmacology identified 6 active components, 255 targets, 5 hub targets (SRC, ESR1, BCL2, HSP90AA1, PPARG) and 20 enriched pathways related to cancer and calcium signalling. CER flavonoid fractions demonstrate antioxidant and antiproliferative activities against A549 cells via multi-component, multi-target mechanisms, supporting its potential clinical application in lung cancer therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: